Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies.

Size: px
Start display at page:

Download "Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies."

Transcription

1 THE POWER OFx MEDPACE ADVANTAGE FOR LIPID STUDIES Experts. Experience. Execution. Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies. Medpace full service specialty teams have conducted over 150 lipid studies over the past 20 years. Medpace noted medical experts, highly experienced clinical trial management teams, central labs, imaging and cardiovascular core labs can bring sponsors one stop solutions for conducting effective and efficient lipid studies. Since its inception in 1992, the advancement of novel therapies for metabolic and endocrine disorders has been a primary therapeutic focus for Medpace. Led by an international team of medical and regulatory experts, our company has helped pioneer mainstay therapies that have revolutionized the care and quality of life for patients. This experience spans a broad array of trial designs, drug classes, and disease endpoints and includes all phases of clinical research. The Medpace team s years of experience conducting metabolic and endocrine studies is unmatched by any other Clinical Research Organization. Highlights Unsurpassed regulatory experience in chronic metabolic and endocrine disorders Operational staff with proven track record of rapid study start-up, successful recruitment and retention, high quality site monitoring and oversight, and proactive risk mitigation One of the most extensive selections of metabolic biomarkers for clinical trials via Medpace Central Laboratories (US, Europe, China and Singapore) Existing investigative site relationships with local KOLs who specialize in recruiting patients with lipid disorders

2 Page 2 of 5 Medpace Experience in Lipid Studies Pioneer in the development of key statins over the past 25 years including: atorvastatin (Lipitor) fluvastatin (Lescol) rosuvastatin (Crestor) simvastatin (Zocor) Over 150 lipid trials involving more than 34,000 patients at more than 2,500 sites Closely involved with the development of most of the lipid agents that have received marketing approval over the last 20 years Statins, fibrates, niacin, bile-acid sequestrants, ezetimibe, omega 3 fatty acid products, RNA targeted therapies, PCSK9, as well as numerous other experimental compounds 30 NDAs- 7 have been related to lipids Additional FH experience Conducted over 20 studies in FH 9 involving HoFH patients involving pediatric populations Provided full service for most of these studies on a global scale Collaboration with opinion leaders in the lipid field and longstanding relationships with key Investigators worldwide Specifically, Medpace has relationships with Investigators at specialized lipid sites that utilize up-to-date databases of their FH patients Ability to leverage these relationships, contributing to accurate feasibility assessments that determine whether the objectives of a particular study can be met within proposed timelines Medpace Central Labs Robust experience supporting key global lipid studies Medpace Central Laboratories delivers key support for fully integrated studies on a global stage by providing consistency in methods and instrumentation across wholly owned and purpose built laboratories around the world. Medpace Central Laboratories has provided core laboratory support to trial sites in 6 continents with truly stellar performance. Medpace Central Labs has conducted some of the largest lipid studies over the past 30 years directed by industry KOLs in Lipidology.

3 Page 3 of 5 Scientific Leadership Traci Turner, MD Executive Director, Central Labs and Metabolic Atherosclerosis Research Center (MARC) Dr. Traci Turner is in Internal Medicine, is a Diplomate with the American Board of Clinical Lipidology, and serves as the Executive Director of Medpace Central Laboratory Operations and the Metabolic and Atherosclerosis Research Center. A native of Cincinnati, OH, she attended the University of Cincinnati and graduated with a BS in Medical Technology, where she also earned her medical degree. Dr. Turner completed her residency at University Hospital in Cincinnati, Ohio. Prior to joining Medpace, Dr. Turner s experience includes 15 years in central laboratory operations supporting the pharmaceutical industry and 7 years in practice specializing in Internal Medicine. KOL Leadership: Evan Stein, MD, PhD, Sr. Consultant Medpace Central Labs, was originally founded by Evan Stein, MD, PhD in 1987 as Medical Research Laboratories. Dr. Stein is considered a foremost expert on the study of lipids. Dr. Stein has held a number of appointments to the NIH, including the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the NHLBI Program on Genetics in Hypertension. From , he was appointed to the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel. Dr. Stein is an accomplished researcher in the of lipid metabolism with extensive publications in this He is an authority on the clinical treatment of hyperlipidemia, as well as on the laboratory measurements of lipid parameters. Dr. Stein consults with many pharmaceutical companies on the development programs for lipid-lowering drugs and participates in many Advisory Boards for these companies. Global Laboratory Studies in Lipidology With laboratories in the US, Europe, China and Singapore, Medpace Labs has the global reach and capabilities to conduct a wide variety of lipid studies in concert with Medpace CRO or as a standalone service. Medpace Central Laboratories has experience in conducting large Phase II-III global studies. Select Medpace Central Lab Lipid studies include: Phase Indication III Dyslipidemia 48 II Hypercholesterolemia 37 III Hyperlipidemia 26 III Hypercholesterolemia 18 II Hypercholesterolemia 10 III Hypercholesterolemia 10 # Of Countries # Sites # Randomized 1, ,737 1,290 3,666 1, Medpace Lab Locations BE, CN, SG, & US BE & US BE & US

4 Page 4 of 5 Phillippa Miranda, MD Senior Medical Director Dr. Miranda received her M.D. from Duke University School of Medicine and completed her residency in Internal Medicine and her fellowship in Endocrinology at Duke. She served on the faculty in the Division of Endocrinology at Duke University Health System for five years prior to transitioning to industry. Dr. Miranda is board certified in Endocrinology, Diabetes, and Metabolism. Her therapeutic expertise covers a wide range of metabolic indications with significant medical monitoring experience in the areas of type 2 diabetes, type 1 diabetes, obesity, and hyperlipidemia. Dr. Miranda has over nine years of experience conducting clinical research studies and is well versed in the conduct of Phase 2 and 3 studies in endocrinology. Alicia Weeks, MD Medical Director Alicia Weeks is an experienced Clinical Endocrinologist with a former academic clinical practice and translational research experience in Type 2 Diabetes. As a Medical Director at Medpace, she provides medical management and expertise to all phases of studies and clinical trials, as well as assists with new business development through participation in proposal and Sponsor meetings. Dr. Weeks gained experience from a dual appointment as a clinical instructor at the University of Wisconsin Hospital & Clinics and as a Research Fellow at the William S. Middleton Memorial Veterans Hospital after earning her medical degree from the Wright State University Boonshoft School of Medicine. Dr. Weeks completed her residency at the Kettering Medical Center and an endocrinology fellowship at the University of Wisconsin. There she was awarded the Dickie Research Award for her significant research contribution toward advancing the field of medicine. Prior to entering the field of medicine, Dr. Weeks worked in the pharmaceutical industry within validation after earning a Bachelor s of Science in Chemical Engineering (BSChE) from the University of Cincinnati. Dr. Weeks is board certified in both Internal Medicine and Endocrinology.

5 Page 5 of 5 Gretchen Williamson, MD, FAAP Medical Director Dr. Williamson completed residency training at Penn State Hershey Medical Center and has post-graduate experience in pediatric endocrinology from Cincinnati Children s Hospital. She has clinical research experience in diabetes, hypercholesterolemia, hypertriglyceridemia, and multiple orphan indications (including familial chylomicronemia). She also has protocol development experience for numerous therapeutic areas, including rheumatoid arthritis, hypogonadism, pancreatic insufficiency, growth hormone deficiency, and stem cell therapies. About Medpace Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries. FOCUSED. TRUSTED. GLOBAL. medpace.com info@medpace.com North America Europe Latin America Asia Africa Middle East Australia

RARE DISEASE. THE POWER OFx. Experts. Experienc e. Execution. Challenges Conducting Rare Disease Studies. Experts: Experience: Execution:

RARE DISEASE. THE POWER OFx. Experts. Experienc e. Execution. Challenges Conducting Rare Disease Studies. Experts: Experience: Execution: THE POWER OFx TM Experts. Experienc e. Execution. The Power of X in Rare Disease Experts: Committed cross-functional team of Rare Disease experts comprised of doctors, project managers, regulatory consultants,

More information

PEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution:

PEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution: THE POWER OFx Experts. Experienc e. Execution. Medpace combines expertise, experience and execution for a winning combination in pediatric studies Experts: Key pediatricians on staff who are trained in

More information

PSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development

PSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Psychiatry Incidences of mental disorders such as depression, bipolar, anxiety disorders, and schizophrenia continue to grow around the

More information

NEUROSCIENCE. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Neurology. Scientifically-Driven Clinical Development

NEUROSCIENCE. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Neurology. Scientifically-Driven Clinical Development THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Neurology Medpace supports our sponsors who are advancing new neurological products by providing specialized expertise in the design and

More information

PEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution:

PEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution: THE POWER OFx Experts. Experienc e. Execution. Medpace combines expertise, experience and execution for a winning combination in pediatric studies Experts: Five key pediatricians on staff who are trained

More information

CARDIOVASCULAR. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Cardiovascular Clinical Development

CARDIOVASCULAR. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Cardiovascular Clinical Development THE POWER OFx A Deeper Dive into Cardiovascular Clinical Development As a therapeutically-focused CRO with a long history in supporting drugs, biologics, and medical devices for cardiovascular disease,

More information

SUBSTANCE USE DISORDERS

SUBSTANCE USE DISORDERS THE POWER OFx SUBSTANCE USE DISORDERS Experts. Experience. Execution. Deep Dive: Substance Use Disorder Clinical Research Accelerate your next substance use disorder study with Medpace s noted medical

More information

HEMATOLOGY AND ONCOLOGY

HEMATOLOGY AND ONCOLOGY x THE POWER OF HEMATOLOGY AND ONCOLOGY Experts. Experience. Execution. A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing

More information

How Medpace Addresses the Unique Challenges in Rare Disease Clinical Research

How Medpace Addresses the Unique Challenges in Rare Disease Clinical Research THE POWER OFx Experts. Experience. Execution. How Medpace Addresses the Unique Challenges in Rare Disease Clinical Research Applying lessons learned, innovative thinking, and creative problem solving By

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

THE POWER OFx RARE DISEASE IN CNS AND NEUROMUSCULAR CONDITIONS. Experts. Experience. Execution. OUR INTEGRATED APPROACH

THE POWER OFx RARE DISEASE IN CNS AND NEUROMUSCULAR CONDITIONS. Experts. Experience. Execution. OUR INTEGRATED APPROACH THE POWER OFx RARE DISEASE IN CNS AND NEUROMUSCULAR CONDITIONS Experts. Experience. Execution. Deep Dive: Rare Disease in CNS and Neuromuscular Conditions Accelerate your next study with Medpace s noted

More information

STROKE CLINICAL RESEARCH

STROKE CLINICAL RESEARCH THE POWER OFx STROKE CLINICAL RESEARCH Experts. Experience. Execution. Deep Dive: Stroke Clinical Research Accelerate your next stroke study with Medpace s noted medical and regulatory experts, highly

More information

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

More information

Management of Post-transplant hyperlipidemia

Management of Post-transplant hyperlipidemia Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and

More information

It is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:

It is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met: Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal

More information

11. December 2017 Marianne Birkeland Kjær

11. December 2017 Marianne Birkeland Kjær 1 11. December 2017 Marianne Birkeland Kjær Presentation title Date 2 Agenda My Background Novo Nordisk Overview PhD and PostDoc opportunities How to apply for regular positions Novo Nordisk standard recruitment

More information

Israel Makov President and Chief Executive Officer Teva

Israel Makov President and Chief Executive Officer Teva Israel Makov President and Chief Executive Officer Israel Makov has been the President and Chief Executive Officer of since April 2002. Previously he served as 's Chief Operating Officer from January 1,

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha

More information

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal

More information

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY

More information

University of Cincinnati Heart, Lung & Vascular Institute

University of Cincinnati Heart, Lung & Vascular Institute University of Cincinnati Heart, Lung & Vascular Institute The nucleus for research and discovery, patient-centered clinical care and academic excellence. University of Cincinnati Heart, Lung & Vascular

More information

A Deeper Dive into Hematology and Oncology

A Deeper Dive into Hematology and Oncology DEEP DIVE A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing specialized expertise in the design and management of your programs.

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

ANCHOR Study Results Overview

ANCHOR Study Results Overview TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company

More information

B. Patient has not reached the percentage reduction goal with statin therapy

B. Patient has not reached the percentage reduction goal with statin therapy Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

More information

Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help. Regulatory Support for Tobacco Products Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help. PREMARKET TOBACCO (PMTA) HUMAN FACTORS STUDIES SUBSTANTIAL EQUIVALENCE

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)

More information

Excellence in Trial Management

Excellence in Trial Management Excellence in Trial Management COMPANY OVERVIEW Privately held company Founded in 2007 Contract Research Organization HQ in Montréal, Canada Specialized in Clinical Development & Trial Management Client

More information

Ready for a CRO That Values Performance Over Promises? CHALLENGE. At Clinipace, it s personal.

Ready for a CRO That Values Performance Over Promises? CHALLENGE. At Clinipace, it s personal. Ready for a CRO That Values Performance Over Promises? CHALLENGE At Clinipace, it s personal. Who We Are At Clinipace, It s Personal. We Will PROVE IT. With us, you get the A team. We deliver a level of

More information

Next Generation Lipid Modification in Cardiovascular Disease

Next Generation Lipid Modification in Cardiovascular Disease TM Next Generation Lipid Modification in Cardiovascular Disease Investor Presentation Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements,

More information

Clinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19

Clinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19 Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

2019 CURRICULUM VITAE

2019 CURRICULUM VITAE 2019 CURRICULUM VITAE Harold E. Bays MD, FOMA, FTOS, FACC, FACE, FNLA Medical Director / President Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC Research Center) 3288 Illinois Avenue

More information

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco Strategic Plan 2013 2017 Executive Summary Society for Research on Nicotine and Tobacco Prepared By: Corona Insights Corona Insights, 2012 CoronaInsights.com CONTENTS Introduction... 1 Background... 1

More information

Maximize the value of your diabetes population management program with advanced analytics PLAYBOOK

Maximize the value of your diabetes population management program with advanced analytics PLAYBOOK Maximize the value of your diabetes population management program with advanced analytics PLAYBOOK STEP ONE: Analyze your patient population Bend the cost curve: Learning more about your patients can lead

More information

BATTELLE CANCER RESEARCH INITIATIVE. Bridging the Gap between Discovery and Application

BATTELLE CANCER RESEARCH INITIATIVE. Bridging the Gap between Discovery and Application BATTELLE CANCER RESEARCH INITIATIVE Bridging the Gap between Discovery and Application ANSWERING THE CALL TO END CANCER Defeating cancer is among the most complex and ambitious goals mankind has ever attempted.

More information

SURVEY REPORT CLINICAL TRIALS: PAST, PRESENT AND FUTURE

SURVEY REPORT CLINICAL TRIALS: PAST, PRESENT AND FUTURE SURVEY REPORT CLINICAL TRIALS: PAST, PRESENT AND FUTURE + OVERVIEW Clinical trials have changed dramatically in the last 10 years. Sponsors are increasingly pressured to get drugs to market faster and

More information

FULL TEXT Associate Professor Dr Poh Kian Keong Dr Peter Yan Chee Hong

FULL TEXT Associate Professor Dr Poh Kian Keong Dr Peter Yan Chee Hong FULL TEXT A recent Dyslipidemia International Study (DYSIS), which was carried out in Asia Pacific countries including four hospitals in Singapore, revealed that a large percentage of local patients with

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Pharmacy Drug Class Review

Pharmacy Drug Class Review Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES

More information

A distinction worth noting. All Doctors of Optometry may use the OD degree after their names... A special few may also use FAAO.

A distinction worth noting. All Doctors of Optometry may use the OD degree after their names... A special few may also use FAAO. A distinction worth noting. All Doctors of Optometry may use the OD degree after their names... A special few may also use FAAO. Excellence in the Practice of Optometry Fellows of the American Academy

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization

More information

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity

More information

R e s e a r c h S t r a t e g y

R e s e a r c h S t r a t e g y Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Specialised Cancer R e s e a r c h S t r a t e g y Academic Directorate of Specialised Cancer Research Strategy Executive Summary

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

The PeriRx, LLC Executive Team

The PeriRx, LLC Executive Team The PeriRx, LLC Executive Team Stephen M. Swanick / President, CEO and Founder Mr. Swanick is the President, Chief Executive Officer and Founder of PeriRx, LLC. PeriRx was formed by Mr. Swanick as a premier

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Learning Objectives. Patient Case

Learning Objectives. Patient Case Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha

More information

Digestive & Metabolic Diseases

Digestive & Metabolic Diseases 4 th World Congress on Digestive & Metabolic Diseases October 29-30, 2018 San Francisco, California, USA Invitation Dear Attendees, We are glad to announce the 4 th World Congress on Digestive & Metabolic

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 Is Universal Pediatric Lipid Screening Justified? YES Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 None Disclosures What is a Pediatrician? Pediatrics is the specialty of medical science

More information

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential

More information

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns

More information

FELLOWSHIP OPPORTUNITIES ADVANCE THE UNDERSTANDING OF AUTISM

FELLOWSHIP OPPORTUNITIES ADVANCE THE UNDERSTANDING OF AUTISM OPPORTUNITIES ADVANCE THE UNDERSTANDING OF AUTISM PREDOCTORAL OPPORTUNITIES Marcus Autism Center, in conjunction with Children s Healthcare of Atlanta and Emory University School of Medicine, is offering

More information

Continuing Medical Education the Joslin Way:

Continuing Medical Education the Joslin Way: Continuing Medical Education the Joslin Way: Superior content Content produced by the most respected experts in diabetes and its related conditions, ensuring that each academic program is timely, accurate,

More information

Pravastatin conversion to atorvastatin

Pravastatin conversion to atorvastatin P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology

More information

Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:

Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

R e s e a r c h S t r a t e g y

R e s e a r c h S t r a t e g y Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Urology R e s e a r c h S t r a t e g y Academic Directorate of Urology Research Strategy Contents 1. Executive Summary 2. Current

More information

July 2011 Medical Update Information

July 2011 Medical Update Information July 2011 Medical Update Information Simvastatin (Zocor) new FDA restrictions FDA statement June 2011 Based on the SEARCH 7 year trial in patients who were considered stable after have had a heart attack.

More information

Abt Associates Inc. Immunization and Health Services Research Helping our clients address critical health issues around the world

Abt Associates Inc. Immunization and Health Services Research Helping our clients address critical health issues around the world Abt Associates Inc. Immunization and Health Services Research Helping our clients address critical health issues around the world Applying our advanced research capabilities to a wide range of health challenges

More information

Transforming health through IT

Transforming health through IT @himsseurope HIMSS Europe 02 HIMSS Europe www.himss.eu The Leading Health IT Knowledge Organisation HIMSS Europe is a voice, advisor and thought leader of transformation through health IT. As an independent

More information

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Pharmaceutical Help to Control Cholesterol

Pharmaceutical Help to Control Cholesterol Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,

More information

Use and Perception of Scientific Medical Reprints

Use and Perception of Scientific Medical Reprints TITLE OF PRESENTATION Use and Perception of Scientific Medical Reprints Elsevier Health Panel Research Report Date August 2017 I 2 Report Structure Research Objectives, Methodology & Sample Executive Summary

More information

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict

More information

Diversity Clinical Research Workshop Invited Faculty

Diversity Clinical Research Workshop Invited Faculty Diversity Clinical Research Workshop Invited Faculty Alex A. Adjei, MD, PhD, FACP Professor and Chair, Department of Medicine Senior Vice President of Clinical Research The Katherine Anne Gioia Chair in

More information

DOWNLOAD OR READ : TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA IN THE PREVENTION OF CORONARY HEART DISEASE PDF EBOOK EPUB MOBI

DOWNLOAD OR READ : TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA IN THE PREVENTION OF CORONARY HEART DISEASE PDF EBOOK EPUB MOBI DOWNLOAD OR READ : TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA IN THE PREVENTION OF CORONARY HEART DISEASE PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of severe hypercholesterolemia pdf Pure hypercholesterolemia

More information

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American

More information

Partnering for Growth

Partnering for Growth Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities

More information

Early Clinical Development #1 REGN727: anti-pcsk9

Early Clinical Development #1 REGN727: anti-pcsk9 Early Clinical Development #1 REGN727: anti-pcsk9 July 15, 2010 Neil Stahl, Ph.D. Senior Vice President Research and Development Sciences 1 Safe Harbor Statement Except for historical information, the

More information

Is patient?: Adult of any age with CVD risk factors; Female >50 or post-menopausal; Diagnosed CAD, PVD, TIA/ Stroke, Diabetes, CKD

Is patient?: Adult of any age with CVD risk factors; Female >50 or post-menopausal; Diagnosed CAD, PVD, TIA/ Stroke, Diabetes, CKD THE CHAMPLAIN PRIMARY CARE Source: J. Genest, R. McPherson, J. Frohlich, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of

More information

The Dental Corporation Opportunity

The Dental Corporation Opportunity The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,

More information

Mayo Clinic Gynecologic Oncology Fellowship (Minnesota) Competency-based goals

Mayo Clinic Gynecologic Oncology Fellowship (Minnesota) Competency-based goals Mayo Clinic Gynecologic Oncology Fellowship (Minnesota) Competency-based goals 1. PATIENT CARE (includes surgical skills) To train gynecologic oncology fellows to competency in evaluation, treatment and

More information

FINAL ENDURING OUTCOMES REPORT

FINAL ENDURING OUTCOMES REPORT FINAL ENDURING OUTCOMES REPORT OVERVIEW This report summarizes consolidated outcomes data from an enduring satellite symposium activity that was launched In March 2017 and ran for 12 months, cumulatively,

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)

More information

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be Ending the Myths: Best Practice in Trial Conduct in Latin America Katie Margules Global Vice President Alliance Management Covance Disclaimer The views and opinions expressed in the following PowerPoint

More information

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,

More information

MEMBERSHIP ENGAGEMENT. Association Executives. International Association of Facilitators (IAF) PUBLISHED BY.

MEMBERSHIP ENGAGEMENT. Association Executives. International Association of Facilitators (IAF) PUBLISHED BY. MEMBERSHIP ENGAGEMENT International Association of Facilitators (IAF) PUBLISHED BY THE ASSOCIATION OF Association Executives ASSOCIATION SUCCESS STORY PROJECT SUCCESS ACHIEVED ORGANISATION DATES CATEGORIES

More information

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring

More information

Making a Difference. Highest quality care. Education. Research. Innovation. OUR MISSION:

Making a Difference. Highest quality care. Education. Research. Innovation. OUR MISSION: Making a Difference Highest quality care. Education. Research. Innovation. OUR MISSION: To deliver world-class care on a daily basis to our patients using the most advanced technologies available. To conduct

More information

Opportunity Knocks: FDA/CDRH Medical Device Fellowship and External Expertise

Opportunity Knocks: FDA/CDRH Medical Device Fellowship and External Expertise Opportunity Knocks: FDA/CDRH Medical Device Fellowship and External Expertise Nancy J. Pluhowski Director, Office of the Center Director Center for Devices and Radiological Health (CDRH), FDA Stanford

More information

ABA. The American Board of Anesthesiology. Media Kit

ABA. The American Board of Anesthesiology. Media Kit ABA The American Board of Anesthesiology Media Kit ABOUT THE ABA The American Board of Anesthesiology (ABA) is a nonprofit organization whose mission is to advance the highest standards of the practice

More information

Young high risk patients the role of statins Dr. Mohamed Jeilan

Young high risk patients the role of statins Dr. Mohamed Jeilan Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures

More information

Hyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center

Hyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology

More information

CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK?

CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK? 1 CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK? Perry J Weinstock, MD, F.A.C.C. Head, Division of Cardiovascular Disease Director of Clinical Cardiology Cooper

More information

SUGAR, OBESITY AND DIABETES THE OTHER GLOBAL FOOD CRISIS

SUGAR, OBESITY AND DIABETES THE OTHER GLOBAL FOOD CRISIS Health & Life Sciences SUGAR, OBESITY AND DIABETES THE OTHER GLOBAL FOOD CRISIS A CROSS-SECTOR APPROACH TO DIET-RELATED CHRONIC DISEASE A breakfast discussion as part of Oliver Wyman s participation in

More information

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,

More information

The potential of South East Asia and India as the hub for vaccine studies

The potential of South East Asia and India as the hub for vaccine studies The potential of South East Asia and India as the hub for vaccine studies Angela Chen Therapeutic Strategy Lead 16 November 2017 Copyright 2017 IQVIA. All rights reserved. The potential of South East Asia

More information

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim

More information

igh-sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies Friday May 30, 2014

igh-sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies Friday May 30, 2014 8:50-9:00 Welcome and Introduction Juravinski Cancer Center Lecture Theatre (4 th floor) 699 Concession St. Hamilton, ON L8V 5C2 Introduction to High-Sensitivity Cardiac Troponin Current State 9:00-9:45

More information

CELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH

CELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH CELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH Our MISSION Building on our tradition Reaching out to the community Doing our best to serve, care and heal Together, we aim

More information

CPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction

CPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction CPE Session 7 Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction Saturday, April 25, 2015 ACPE UAN 0128-0000-15-027-L01-P 1.0

More information

Lung Cancer Screening

Lung Cancer Screening Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas

More information

SciVal Research Intelligence Tool

SciVal Research Intelligence Tool 0 SciVal Research Intelligence Tool Alexander van Servellen Consultant, Elsevier Research Intelligence a.vanservellen@elsevier.com Mahidol University, May 21st 2015 1 Context Mahidol University subscribes

More information

Tuberous Sclerosis Complex Research Program

Tuberous Sclerosis Complex Research Program Tuberous Sclerosis Complex Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military,

More information